What the FDA labels say about taking them together
Insulin detemir and pramlintide
Insulin detemir's FDA label of October 9, 2024 names pramlintide in its drug interactions section; pramlintide's label does not name insulin detemir itself but warns about its class (insulin analogs). The insulin detemir label: “… disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 …”
Check it at the source: the insulin detemir FDA label on DailyMed (effective October 9, 2024); the pramlintide FDA label on DailyMed (effective December 18, 2019, AstraZeneca Pharmaceuticals LP).
What does the insulin detemir label say about pramlintide?
Insulin detemir label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. Intervention: Dosage reductions and increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs.
Source: FDA drug label (Levemir), A-S Medication Solutions, effective October 9, 2024 (SPL set 82192527-99aa-4b53-8ce9-9173668d309c), via openFDA; the full label on DailyMed
What does the pramlintide label say about insulin detemir?
Pramlintide's label does not name insulin detemir itself; it warns about its class (insulin analogs):
Pramlintide label, boxed warningSEVERE HYPOGLYCEMIA SYMLIN use with insulin increases the risk of severe hypoglycemia, particularly in patients with type 1 diabetes.
Pramlintide label, boxed warningAppropriate patient selection, careful patient instruction, and insulin dose reduction are critical elements for reducing this risk.
Source: FDA drug label (SymlinPen), AstraZeneca Pharmaceuticals LP, effective December 18, 2019 (SPL set 4aea30ff-eb0d-45c1-b114-3127966328ff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin detemir | Pramlintide | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once